12,372 trials
Chronic Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 93.6; 96.4; 99.1; 99.1 percentage of participants…
Epilepsy
Primary: Retention at the End of the 21-week Treatment Period — 73.3 percentage of participants
Light Chain Deposition Disease · Primary Systemic Amyloidosis
Primary: Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR])…
Acne Vulgaris
Primary: Absolute Change in Total Lesion Count From Baseline to Week 12 — -55.7; -51.2 Change in lesion count — p=0.002
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 85 — -0.020; 0.103; 0.108 Liters — p=< 0.001
Locally Advanced or Metastatic Medullary Thyroid Cancer · Medullary Thyroid Cancer
Primary: Percentage of Time a Patient Experienced at Least 1 AE of CTCAE Grade >=2 in First 12 Months of Receiving Vandetanib in Patients Who Participated in Patient Outreach…
Type 2 Diabetes
Primary: Incidences of Adverse Events — 48; 57 Participants
Leukaemia
Primary: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) — 5.36; 3.61; 10.05; 7.16 Months — p=0.2677
HIV-1 Infection
Primary: Proportion of Patients With Treatment Failure (TF) — 27.5; 15.4; 7.9; 15.4 percentage of patients
Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Participants With Sustained Accumulation of Disability (SAD) — 11.12; 8.00 percentage of participants with SAD — p=0.2173
Chronic Hepatitis C
Primary: The Primary Endpoint Would be the Number Who Achieve a Sustained Virologic Response. — 11; 10 participants
Hepatitis C · Human Immunodeficiency Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 88.5; 66.7; 91.7; 94.1 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 — 2.63; 1.94 Months — p=0.0103
Obesity · Overweight
Primary: Co-primary: Body Weight- Mean Percent Change — -9.29; -5.08 percentage of body weight — p=<0.001
Obesity · Overweight
Primary: Co-primary: Body Weight- Mean Percent Change — -5.00; -6.14; -1.33 percentage of body weight — p=<0.001